Brazil says Chinese vaccine trial can resume

By Anthony Boadle BRASILIA (Reuters) - Brazill health regulator Anvisa on Wednesday allowed resumption of late-stage clinical trials for China's Sinovac COVID-19 vaccine, which had been suspended due to the death of a study subject that was registered in Sao Paulo as a suicide. Brazil's President Jair Bolsonaro, a longtime China skeptic who has baselessly dismissed the Sinovac vaccine as lacking in credibility, had hailed Monday's suspension as a personal victory. The decision was severely criticized by the trial organizers, who said the move had taken them by surprise and that there had been no need to stop the study as the death had no relation to the vaccine

Reuters November 12, 2020 00:06:02 IST
Brazil says Chinese vaccine trial can resume

Brazil says Chinese vaccine trial can resume

By Anthony Boadle

BRASILIA (Reuters) - Brazill health regulator Anvisa on Wednesday allowed resumption of late-stage clinical trials for China's Sinovac COVID-19 vaccine, which had been suspended due to the death of a study subject that was registered in Sao Paulo as a suicide.

Brazil's President Jair Bolsonaro, a longtime China skeptic who has baselessly dismissed the Sinovac vaccine as lacking in credibility, had hailed Monday's suspension as a personal victory.

The decision was severely criticized by the trial organizers, who said the move had taken them by surprise and that there had been no need to stop the study as the death had no relation to the vaccine.

The suspension further inflamed tensions between Bolsonaro and Sao Paulo Governor Joao Doria, who has pinned his political ambitions on the Chinese vaccine that he aims to roll out in his state as early as January, with or without federal assistance.

Anvisa, in its statement on Wednesday, said the initial information it received about the case, which led to the suspension, had been incomplete and lacked the cause of the "severe adverse event." It has strongly dismissed suggestions the decision could have been politically motivated.

"After evaluating the new data presented by the sponsor ... Anvisa understands that it has sufficient reasons to allow the resumption of vaccination," the agency said.

"It is important to clarify that a suspension does not necessarily mean that the product under investigation does not offer quality, safety or efficacy," Anvisa added.

Brazil has one of the world's worst COVID-19 outbreaks, with over 5.7 million confirmed cases and 163,000 deaths related to the virus. Bolsonaro has come under fire for his constant dismissal of the virus and its dangers.

On Tuesday, Bolsonaro said Brazilians "must stop being sissies" about the virus, adding "we are all going to die one day."

(Reporting by Anthony Boadle; Writing by Anthony Boadle and Jamie McGeever; Editing by Stephen Eisenhammer and Bill Berkrot)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

U.S. data suggest economic recovery may be weakening
Business

U.S. data suggest economic recovery may be weakening

By Howard Schneider WASHINGTON (Reuters) - The explosive surge in U.S. coronavirus cases this fall has left a question hanging: When will the economy take its own turn for the worse

Fed, ECB heads give COVID-19 vaccine cautious welcome
Business

Fed, ECB heads give COVID-19 vaccine cautious welcome

FRANKFURT/WASHINGTON (Reuters) - The heads of the Federal Reserve and the European Central Bank welcomed the encouraging results in trials of a vaccine candidate for the novel coronavirus but stressed that the economic outlook will remain uncertain. Fed chair Jay Powell and ECB President Christine Lagarde said the economy was still in for a tough time even if the development of a potential vaccine by U.S. drugmaker Pfizer and German partner BioNTech SE was reason for some optimism further ahead

India's October fuel demand marks first year-on-year gain in 8 months
Business

India's October fuel demand marks first year-on-year gain in 8 months

By Sumita Layek (Reuters) - India's fuel consumption in October registered its first year-on-year increase since February, as slowing coronavirus cases and increased mobility accelerated an economic recovery, data showed on Thursday.